T cells play a critical role in cancer control, but a range of potent immunosuppressive
mechanisms can be upregulated in the tumor microenvironment (TME) to abrogate their …

Immune checkpoint antagonists (CTLA-4 and PD-1/PD-L1) and CAR T-cell therapies
generate unparalleled durable responses in several cancers and have firmly established …

As a new pillar of cancer therapy, tumor immunotherapy has brought irreplaceable durable
responses in tumors. Considering its low response rate, additional immune regulatory …

Cancer immunotherapy based on immune-checkpoint inhibition or adoptive cell therapy has
revolutionized cancer care. Nevertheless, a large proportion of patients do not benefit from …

Increasing evidence supports targeting the adenosine pathway in immuno-oncology with
several clinical programs directed at adenosine A2 receptor (A2AR, A2BR), CD73 and …

Introduction: The adenosine pathway plays a key role in modulating immune responses in
health and in disease. In health, anti-inflammatory effects of adenosine balance pro …

Within tumors, some areas are less oxygenated than others. Since their home ground is
under chronic hypoxia, tumor cells adapt to this condition by activating aerobic glycolysis; …

The immune system plays a major role in the surveillance and control of malignant cells,
with the presence of tumor infiltrating lymphocytes (TILs) correlating with better patient …

Purpose: There are several agents in early clinical trials targeting components of the
adenosine pathway including A2AR and CD73. The identification of cancers with a …

Accumulation of extracellular adenosine within the microenvironment is a strategy exploited
by tumors to escape detection by the immune system. Adenosine signaling through the …